VistaGen Therapeutics (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medicines that go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's three CNS drug candidates, PH94B, PH10, and AV-101, has a differentiated mechanism of action, a favorable safety profile in all clinical studies to date, and therapeutic potential in multiple CNS markets.
343 Allerton Avenue
South San Francisco, CA 94080
Pharmaceutical Preparation Manufacturing (325412)
Pharmaceutical Preparations (2834)